Abstract: Recombinant protein purification vectors and methods for their use are disclosed. The vectors contain a DNA sequence coding for a gelatin binding region of fibronectin. The vectors express a foreign DNA sequence of interest fused to the fibronectin portion. Secretion signals on the fused product assist the product in being secreted from a production cell. The product can then be purified on a gelatin-containing affinity column and digested with a protease, such as trypsin, to cleave the desired protein from the gelatin binding region. The protein then contains no more than one extraneous amino acid.

Abstract: A process for the preparation of a polypeptide of the formula ##STR1## wherein A' is Pro, Gly, Asp or Ser; B' is Gly, Asn or Ser; C is Gln, Glu or Asp; D is Asn, Glu or Asp; X' is a residue of amino acid other than Met; E is Gln, Lys or Arg, and Y' is a residue of homoserine or homoserine-lactone, as well as a recombinant DNA and expression plasmid for preparing the polypeptide.

Abstract: The invention relates to DNA sequences coding for PTH variants, to PTH variants, expression vectors, bacterial hosts, uses and therapeutic compositions.

Abstract: The invention relates to DNA sequences coding for PTH variants, to PTH variants, expression vectors, bacterial hosts, uses and therapeutic compositions.

Abstract: Disclosed are nucleic acid sequences encoding components of the dystrophin-glycoprotein complex. The components include dystroglycan, the 50 kDa protein component and the 59 kDa protein component. Also disclosed are compositions and methods which relate to the disclosed sequences.

Abstract: Improved therapeutic uses of bactericidal/permeability-increasing protein (BPI) involve use of BPI protein product formulations in the form of physiologically stable dimeric associations of BPI protein product monomers characterized by enhanced in vivo biological activity. Preferred formulations include 50 percent or more by weight dimeric product.

Abstract: A new plasmid vector is described which can replicate in B.subtilis and which can express and secrete, in the culture medium, human beta interleukin-1 (beta IL-1) without amino acid sequences extraneous to the natural molecule, a strain of B.subtilis transformed by the vector and a method for the expression and secretion of mature human beta interleukin-1. The human beta interleukin-1 thus obtained shows a specific acitvity of 1.times.10.sup.9 U/mg of protein and is particularly suitable as a stimulant for the immune system, as an adjuvant in vaccines for the activation of the repair mechanism in cases of tissue damage, and for the treatment of auto-immune diseases in man.

Abstract: A DNA polymerase having an amino acid sequence comprising substantially the same amino acid sequence as that of Thermus aquaticus or Thermus flavus DNA polymerase, excluding the N-terminal 280 amino acid residues of Thermus aquaticus DNA polymerase or the N-terminal 279 amino acid residues of Thermus flavus DNA polymerase, recombinant DNA sequences encoding said DNA polymerases, vectors comprising said DNA sequences, and host cells containing such vectors. A formulation of thermostable DNA polymerases comprising a majority component comprised of at least one thermostable DNA polymerase of the type described above, wherein the DNA polymerase lacks 3'-exonuclease activity, and a minority component comprised of at least one thermostable DNA polymerase exhibiting 3'-exonuclease activity, and an improved method for amplifying nucleic acid sequences by polymerase chain reaction wherein the above formulation is mixed and used to catalyze primer extension, are also provided.

Abstract: The present invention provides the isolated DNA sequence encloding the dimer subunit of the lysine-sensitive diaminopimelate decarboxylase from the thermophilic methylotrophic Bacillus sp. MGA3.

Abstract: A DNA gene which encodes transglutaminase, a plasmid in which the DNA gene is incorporated, a transformant transformed with the plasmid and a process for the production of transglutaminase that comprises culturing the transformant.

Abstract: A novel human antithrombin III (AT III) mutant having a high antithrombin activity in the absence of heparin and effective in the treatment of thrombotic disorders as an anticoagulant, which is obtained by mutating amino acids at the reactive site and the heparin binding site of human AT III into another amino acids with the use of the recombinant DNA technology with the use of a DNA coding for AT III as a template. The invention also relates to a method for mass producing the above-described mutant by incubating a host transformed by an expression vector having the cDNA of the mutant inserted therein.

Abstract: Phosphorylated plasminogen activator, such as phosphorylated pro-urokinase (pro-u-PA), which is substantially free from unphosphorylated plasminogen activator, may be obtained by phosphorylating unphosphorylated plasminogen activator with a phosphorylating enzyme or by separating phosphorylated plasminogen activator from a mixture of phosphorylated plasminogen activator and unphosphorylated plasminogen activator. Phosphorylated pro-u-PA, which is substantially free from unphosphorylated pro-u-PA, is converted by plasmin into phosphorylated u-PA. The phosphorylated plasminogen activators such as phosphorylated pro-u-PA, u-PA and t-PA are useful as thrombolytic agents.

Abstract: The invention rleates to .gamma.-cyclodextrin glycosyl transferases obtainable by screening bacteria for the secretion of a .gamma.-cyclodextrin glycosyl transferase, the bacteria are characterized and the .gamma.-cyclodextrin glycosyl transferase of the bacteria is purified and characterized biochemically. These enzymes can be used for the production of .gamma.cyclodextrin from starch.

Abstract: Four mutations have been found clustered in exon 11 of the CFTR (cystic fibrosis transmembrane conductance regulator) gene. These mutations occur within a set of amino acids highly conserved among ATP-dependent transport proteins. Humans can be tested to determine whether they carry one of these mutations using a number of methods and/or probes taught herein. Specifically the mutations include: Asn.sub.549, Asp.sub.551, Stop.sub.553, and Thr.sub.559.

Abstract: The present invention describes a variant protein S protein that is substantially homologous in amino acid residue sequence to wild-type mature human protein S, which has in vitro anticoagulant activity and has a reduced ability to bind C4b binding protein (C4BP), compositions containing the variant protein S, and recombinant DNA vectors for expressing the variant protein. Also disclosed are therapeutic methods of using variant protein S for inhibiting thrombosis, inflammation and the like conditions ameliorated by protein S.

Abstract: The invention is stably transfected cells, substantially all of which contain at least one human collagen gene and express fibrillar collagen molecules derived using methods for synthesizing collagen and collagen fibrils in said cell lines, and methods for treatment of disorders in humans using said collagen derived from said stable cell lines.

Abstract: In this patent application we have described the construction of a novel secretion vector based on E. coli enterotoxin coding sequence. We have shown categorically that pre and pro regions of toxin gene are absolutely necessary for extra cellular secretion of the stable toxin. We have also shown with specific examples that when the nucleotide coding sequence of a heterologous peptide is fused in frame to the end of the pro region in the st gene, the resultant vector in an E. coli host secretes extracellularly correctly processed heterologous peptide. This application also includes construction of suitable vectors where this gene fusion can be achieved. Generally methods to create such fusions involving a) recombinant DNA technology and b) the use of site directed in vitro mutagenesis, have also been described. A general method of purification of heterologous peptides is also described in this application.

Abstract: Method of isolating deletion mutants of Vibrio cholerae, wherein the deletion is predetermined by digestion with restriction endonucleases of known specificity. The deletions are inserted into the Vibrio cholerae chromosome by in vivo recombination between a plasmid carrying the desired deletion, with adjacent flanking sequences, and the Vibrio cholerae chromosome. The invention includes the isolation and characterization of a new Vibrio cholerae strain, (ATCC No. 55456), having a deletion in the tox gene, as defined by Acc I, Xba I, Cla I and/or restriction endonuclease sites, and carrying a mercury resistance gene. The invention also includes vaccines for protecting against the symptoms of cholera as well as methods for achieving this protection.

Abstract: The present invention relates to novel purified and isolated nucleotide sequences encoding mammalian Ca.sup.2+ /calmodulin stimulated phosphodiesterases (CaM-PDEs) and cyclic-GMP-stimulated phosphodiesterases (cGS-PDEs). Also provided are the corresponding recombinant expression products of said nucleotide sequences, immunological reagents specifically reactive therewith, and procedures for identifying compounds which modulate the enzymatic activity of such expression products.

Abstract: An anti-coccidial vaccine is provided which contains a recombinant peptide with novel epitopes. The recombinant peptide has an amino-terminal amino acid sequence that is unique among known Eimeria antigens. Recombinant vectors encoding the novel peptide antigen are deposited under ATCC Accession No. 68450, and ATCC Accession No. 68537.